T. Ahmad

891 total citations
12 papers, 677 citations indexed

About

T. Ahmad is a scholar working on Oncology, Molecular Biology and Reproductive Medicine. According to data from OpenAlex, T. Ahmad has authored 12 papers receiving a total of 677 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Molecular Biology and 2 papers in Reproductive Medicine. Recurrent topics in T. Ahmad's work include Melanoma and MAPK Pathways (6 papers), Cutaneous Melanoma Detection and Management (4 papers) and Protein Degradation and Inhibitors (3 papers). T. Ahmad is often cited by papers focused on Melanoma and MAPK Pathways (6 papers), Cutaneous Melanoma Detection and Management (4 papers) and Protein Degradation and Inhibitors (3 papers). T. Ahmad collaborates with scholars based in United Kingdom, United States and India. T. Ahmad's co-authors include Richard Marais, Maggie James, Brian Schwartz, Martin Gore, Tim Eisen, I. Gibbens, Lynn M. Schuchter, Mark J. Ratain, Keith T. Flaherty and Ronit Simantov and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and British Journal of Cancer.

In The Last Decade

T. Ahmad

11 papers receiving 657 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T. Ahmad United Kingdom 7 566 388 87 82 78 12 677
Arthur Groy United States 6 497 0.9× 279 0.7× 43 0.5× 81 1.0× 109 1.4× 7 696
Chenjing Xia China 4 439 0.8× 308 0.8× 56 0.6× 70 0.9× 74 0.9× 9 538
Maggie James United States 8 568 1.0× 412 1.1× 99 1.1× 78 1.0× 80 1.0× 25 721
Kelly E. Fisher United States 4 434 0.8× 288 0.7× 36 0.4× 87 1.1× 91 1.2× 6 599
Kimberly N. Smitheman United States 11 856 1.5× 345 0.9× 67 0.8× 153 1.9× 112 1.4× 11 1.0k
Mary Ellen Simcox United States 8 458 0.8× 351 0.9× 45 0.5× 96 1.2× 111 1.4× 12 643
Marian M. Deuker United States 6 580 1.0× 274 0.7× 56 0.6× 117 1.4× 118 1.5× 6 742
Zoi Karoulia United States 6 560 1.0× 238 0.6× 65 0.7× 115 1.4× 130 1.7× 9 664
Sujatha Nallapareddy United States 10 509 0.9× 440 1.1× 63 0.7× 64 0.8× 103 1.3× 16 790
Allison Marlow United States 3 724 1.3× 447 1.2× 44 0.5× 98 1.2× 166 2.1× 3 946

Countries citing papers authored by T. Ahmad

Since Specialization
Citations

This map shows the geographic impact of T. Ahmad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Ahmad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Ahmad more than expected).

Fields of papers citing papers by T. Ahmad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Ahmad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Ahmad. The network helps show where T. Ahmad may publish in the future.

Co-authorship network of co-authors of T. Ahmad

This figure shows the co-authorship network connecting the top 25 collaborators of T. Ahmad. A scholar is included among the top collaborators of T. Ahmad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Ahmad. T. Ahmad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Vishnu, Venugopalan Y., Richard J.L.F. Lemmers, T. Ahmad, et al.. (2024). The first genetically confirmed cohort of Facioscapulohumeral Muscular Dystrophy from Northern India. European Journal of Human Genetics. 32(9). 1053–1064. 4 indexed citations
2.
3.
Hiley, Crispin T., T. Ahmad, Matthew Krebs, et al.. (2023). LBA72 DARWIN II: Deciphering anti-tumour response and resistance to immunotherapy with intratumour heterogeneity in NSCLC. Annals of Oncology. 34. S1314–S1314.
4.
Eisen, Tim, Richard Marais, Annette Affolter, et al.. (2011). Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. British Journal of Cancer. 105(3). 353–359. 33 indexed citations
5.
Brooke, Antonia, Norman Taylor, J. H. Shepherd, et al.. (2006). A Novel Point Mutation in P450c17 (CYP17) Causing Combined 17α-Hydroxylase/17,20-Lyase Deficiency. The Journal of Clinical Endocrinology & Metabolism. 91(6). 2428–2431. 34 indexed citations
6.
Eisen, Tim, T. Ahmad, Keith T. Flaherty, et al.. (2006). Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. British Journal of Cancer. 95(5). 581–586. 483 indexed citations
7.
Lorigan, Paul, Pippa Corrie, David Chao, et al.. (2006). Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients. Journal of Clinical Oncology. 24(18_suppl). 8012–8012. 17 indexed citations
8.
Eisen, Tim, T. Ahmad, M. Gore, et al.. (2005). Phase I trial of BAY 43–9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. Journal of Clinical Oncology. 23(16_suppl). 7508–7508. 41 indexed citations
9.
Ahmad, T., Richard Marais, L Pyle, et al.. (2004). BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience. Journal of Clinical Oncology. 22(14_suppl). 7506–7506. 39 indexed citations
10.
Ahmad, T., Richard Marais, L Pyle, et al.. (2004). BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience. Journal of Clinical Oncology. 22(14_suppl). 7506–7506. 21 indexed citations
11.
Hubner, Richard, T. Ahmad, Anne Rigg, et al.. (2004). Epirubicin-carboplatin-capecitabine (ECarboX) in relapsed ovarian cancer: A phase I/II trial. Journal of Clinical Oncology. 22(14_suppl). 5109–5109. 2 indexed citations
12.
Hübner, Ralf‐Harto, et al.. (2004). Epirubicin-carboplatin-capecitabine (ECarboX) in relapsed ovarian cancer: A phase I/II trial. Journal of Clinical Oncology. 22(14_suppl). 5109–5109. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arthur Groy Breakdown of academic impact, for papers by Chenjing Xia Breakdown of academic impact, for papers by Maggie James Breakdown of academic impact, for papers by Kelly E. Fisher Breakdown of academic impact, for papers by Kimberly N. Smitheman Breakdown of academic impact, for papers by Mary Ellen Simcox Breakdown of academic impact, for papers by Marian M. Deuker Breakdown of academic impact, for papers by Zoi Karoulia Breakdown of academic impact, for papers by Sujatha Nallapareddy Breakdown of academic impact, for papers by Allison Marlow
Rankless by CCL
2026